Paul Tudor Jones's CRVS Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 27,494 shares of Corvus Pharmaceuticals, Inc. (CRVS) worth $402,237, representing 0.00% of the portfolio. First purchased in 2016-Q1, this short-term holding has been held for 3 quarters.
Based on 13F filings, Paul Tudor Jones has maintained this position in CRVS for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 27,494 shares. Largest reduction occurred in Q2 2016, reducing 10,000 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Corvus Pharmaceuticals (CRVS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Corvus Pharmaceuticals (CRVS) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +27,494 | New Buy | 27,494 | $14.63 |
| Q2 2016 | -10,000 | Sold Out | 0 | $0.00 |
| Q1 2016 | +10,000 | New Buy | 10,000 | $14.50 |
Paul Tudor Jones's Corvus Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased Corvus Pharmaceuticals, Inc. (CRVS) in Q1 2016, acquiring 10,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Corvus Pharmaceuticals, Inc. (CRVS) for 3 quarters since Q1 2016.
Paul Tudor Jones's largest addition to Corvus Pharmaceuticals, Inc. (CRVS) was in Q1 2026, adding 27,494 shares worth $402,237.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 27,494 shares of Corvus Pharmaceuticals, Inc. (CRVS), valued at approximately $402,237.
As of the Q1 2026 filing, Corvus Pharmaceuticals, Inc. (CRVS) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Corvus Pharmaceuticals, Inc. (CRVS) was 27,494 shares, as reported at the end of Q1 2026.